| Bioactivity | Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS) with anti-tumor activity. Lixumistat regulates OXPHOS to attenuate mitochondrial metabolic reprogramming and inhibit lung fibrosis. Lixumistat also suppresses B-cell activation to alleviate systemic lupus erythematosus[1][5]. |
| Target | oxidative phosphorylation (OXPHOS) |
| Name | Lixumistat |
| CAS | 1422365-93-2 |
| Formula | C13H16F3N5O |
| Molar Mass | 315.29 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Willette RN, et al. Modulation of Oxidative Phosphorylation with IM156 Attenuates Mitochondrial Metabolic Reprogramming and Inhibits Pulmonary Fibrosis. J Pharmacol Exp Ther. 2021 Nov;379(3):290-300. [2]. Shim JS, Kim EJ, Lee LE, Kim JY, Cho Y, Kim H, Kim J, Jang SH, Son J, Cheong JH, Kim A, Lim BJ, Ha SJ, Song JJ, Kim BS. The oxidative phosphorylation inhibitor IM156 suppresses B-cell activation by regulating mitochondrial membrane potential and contributes to the mitigation of systemic lupus erythematosus. Kidney Int. 2023 Feb;103(2):343-356. |
Lixumistat
CAS: 1422365-93-2 F: C13H16F3N5O W: 315.29
Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS)
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.